Evidence map›Paper›PMID 34539331›Full record

ArticleFrontiers in neuroscience2021

Neurofilament Light Chain and Intermediate HTT Alleles as Combined Biomarkers in Italian ALS Patients.

Assunta Ingannato, Silvia Bagnoli, Salvatore Mazzeo, Valentina Bessi, Sabrina Matà, Monica Del Mastio, Gemma Lombardi, Camilla Ferrari, Sandro Sorbi, Benedetta Nacmias

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Assunta IngannatoNEUROFARBA Department, University of Florence, Florence, Italy.
Silvia BagnoliNEUROFARBA Department, University of Florence, Florence, Italy.
Salvatore MazzeoNEUROFARBA Department, University of Florence, Florence, Italy.
Valentina BessiNEUROFARBA Department, University of Florence, Florence, Italy.
Sabrina MatàSOD Neurologia 1, Dipartimento Neuromuscolo-Scheletrico e Degli Organi di Senso, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
Monica Del MastioSOD Neurologia 1, Dipartimento Neuromuscolo-Scheletrico e Degli Organi di Senso, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
Gemma LombardiIRCCS Fondazione Don Carlo Gnocchi, Florence, Italy.
Camilla FerrariNEUROFARBA Department, University of Florence, Florence, Italy.
Sandro SorbiNEUROFARBA Department, University of Florence, Florence, Italy.
Benedetta NacmiasNEUROFARBA Department, University of Florence, Florence, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo study the possible implication of the two biomarkers, intermediate alleles (IAs) of the Huntingtin (HTT) gene and neurofilament light chain (NfL) levels in plasma, in amyotrophic lateral sclerosis (ALS) patients.

methodsWe analyzed IAs in a cohort of 106 Italian ALS patients and measured the plasma NfL levels in 20% of the patients of the cohort. We correlated the two biomarkers with clinical phenotypes.

resultsIntermediate alleles were present in 7.5% of the patients of our cohort, a frequency higher than that reported in general population. Plasma NfL levels increased with age at onset (

conclusionAccording to our findings, plasma NfL and IAs of HTT gene may represent potential biomarkers in ALS, providing evidence of a possible implication in clinical phenotype.

Indexed as

amyotrophic lateral sclerosisbiomarkersCAG repeat expansionHTT geneneurofilament light chain

Identifiers

PMID34539331
PMCPMC8446383

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.